1. Home
  2. NGNE vs GCO Comparison

NGNE vs GCO Comparison

Compare NGNE & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$22.28

Market Cap

327.8M

Sector

Health Care

ML Signal

N/A

Logo Genesco Inc.

GCO

Genesco Inc.

N/A

Current Price

$25.12

Market Cap

286.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
GCO
Founded
2003
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
286.0M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
NGNE
GCO
Price
$22.28
$25.12
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
$60.13
$33.00
AVG Volume (30 Days)
157.3K
229.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$925,000.00
$2,606,898,000.00
Revenue This Year
N/A
$2.42
Revenue Next Year
N/A
$3.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.71
52 Week Low
$6.88
$16.19
52 Week High
$37.27
$38.95

Technical Indicators

Market Signals
Indicator
NGNE
GCO
Relative Strength Index (RSI) 56.11 38.19
Support Level $19.44 $21.57
Resistance Level $25.79 $26.28
Average True Range (ATR) 2.28 1.79
MACD 0.24 -0.05
Stochastic Oscillator 51.91 10.90

Price Performance

Historical Comparison
NGNE
GCO

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About GCO Genesco Inc.

Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.

Share on Social Networks: